Revolution Medicines, Inc. (RVMD)

NASDAQ: RVMD · USD

$189

+2.40 (+1.3%)· Recorded snapshot

Market cap	40.4B
Net income (ttm)	-1.8B
EPS (ttm)	-$8.92
Shares out	214.3M
Volume	703,850
Beta	1.40

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -1.8B
EPS (ttm): -$8.92
Market cap: 40.4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-79.1

P25 n/aP50 n/aP75 n/a

ROIC-33.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All RVMD indicators

Market & fundamental data

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001628171
Company name	Revolution Medicines, Inc.
Country	United States
Country code	US
CUSIP number	76155X100
Earnings date	2026-11-04
Earnings time	amc
Employees	883
Employees change	349
Employees growth	65.36%
Enterprise value	$37.7B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
Industry	Biotechnology
IPO date	2020-02-13
Is primary listing	Yes
Is SPAC	No
ISIN number	US76155X1000
Last 10-K release date	2026-02-25
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$40.4B
Market cap category	Large-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$188.63
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	RVMD
U.S. state	California
Website	https://www.revmed.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-4.73%
FCF / EV yield	-3.31%
FCF yield	-3.08%
Forward EV/Sales	53.42x
Forward P/S	57.36x
P/B ratio	15.31x
Price / tangible book value	15.75x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2M
ROA	-30.12%
ROA (5Y)	-21.66%
ROCE	-41%
ROE	-79.09%
ROE (5Y)	-39.1%
ROIC	-33.68%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-9.1M
Depreciation and amortization	$9.1M
EBIT	$-1.6B
EBITDA	$-1.6B
EPS	$-8.92
FCF per share	$-5.75
Financing cash flow	$3B
Free cash flow	$-1.2B
Free cash flow minus SBC	$-1.5B
Gross profit	$-1.3B
Investing cash flow	$-1.4B
Net borrowing	$487.1M
Net cash flow	$413.9M
Net income	$-1.8B
Operating cash flow minus SBC	$-1.4B
Operating income	$-1.6B
Stock-based compensation	$218.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$12.16
Debt / equity	0.46
Goodwill	$14.6M
Interest coverage	-27.42
Long-term assets	$294.9M
Long-term liabilities	$1.4B
Net cash (debt)	$2.7B
Net cash / market cap	6.88%
Net cash growth	56.17%
Net debt / equity	-1.05
Piotroski F-Score	1
Property, plant and equipment	$162.5M
Shareholders' equity	$2.6B
Tangible book value	$2.5B
Tangible book value per share	$11.84
Total assets	$4.3B
Total cash	$3.9B
Total debt	$1.2B
Total liabilities	$1.7B
WACC	11.72%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$4B
Current liabilities	$354.1M
Current ratio	11.38
Net working capital	$-246.9M
Quick ratio	11.12
Working capital	$3.7B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-10.45%
Dividend yield	0%
Shareholder yield	-10.45%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$173.11
1D price change	1.29%
1M price change	-7.97%
1M total return	-7.97%
1W price change	-2.91%
1W total return	-2.91%
1Y price change	225.28%
1Y return CAGR	225.54%
1Y total return	225.28%
20-day SMA	$192.42
200-day SMA	$155.34
3M price change	0.3%
3M total return	0.3%
3Y price change	913.6%
3Y return CAGR	116.38%
3Y total return	913.6%
50-day SMA	$200.12
50-day SMA vs 200-day SMA	50over200
52-week high	$224.31
52-week high date	2026-08-27
52-week low	$56.66
52-week low date	2025-11-03
5Y price change	583.69%
5Y return CAGR	46.89%
5Y total return	583.69%
6M price change	43.26%
6M total return	43.26%
All-time high	$224.31
All-time high date	2026-08-27
All-time low	$14.08
All-time low date	2022-05-12
Average true range (ATR)	$8.60
Average volume	2M
Beta (1Y)	2.96
Beta (2Y)	1.6
Beta (5Y)	1.4
Change from 52-week high	-15.91%
Change from 52-week low	232.92%
Change from all-time high	-15.91%
Change from all-time low	1,239.7%
Change from open	1.85%
Day's gap	-0.54%
Dollar volume	$132.8M
High price	$188.70
Low price	$184.71
Monthly RSI	80.37
Open price	$185.21
Position in 52-week range	98.25%
Premarket change	-0.66%
Premarket close	$186.22
Premarket price	$185.00
Previous close	$186.22
Price vs 150-day SMA	8.97%
Price vs 20-day SMA	-1.97%
Price vs 200-day SMA	21.43%
Price vs 50-day SMA	-5.74%
Relative volume	0.35
Return from IPO open	560.72%
Return from IPO price	996.41%
RSI	46.2
Sharpe ratio	2.02
Sharpe ratio (3Y)	1.63
Sharpe ratio (5Y)	0.87
Sortino ratio	4.64
Sortino ratio (3Y)	3.21
Sortino ratio (5Y)	1.49
Volume	703.9K
Weekly RSI	57.35
YTD price change	136.82%
YTD total return	136.82%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	184.6M
Float percentage	86.13%
Shares change (QoQ)	6.46%
Shares change (YoY)	10.45%
Shares held by insiders	2.17%
Shares held by institutions	90.17%
Shares outstanding	214.3M
Short % of float	7.01%
Short % of shares	6.03%
Short ratio	5.9 days

Deeper analysis on RVMD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RVMD report

Is a complete RVMD research report available?

No complete published report is available for Revolution Medicines, Inc. (RVMD) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Revolution Medicines, Inc. (RVMD)

Price

Financial snapshot

Fair-value bridge

Latest news · RVMD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RVMD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RVMD

Frequently asked questions